The
global pruritus therapeutic market is
expected to grow by USD 3.63 billion as per Technavio. This marks a significant
market slowdown compared to the 2019 growth estimates due to the impact of the
COVID-19 pandemic in the first half of 2020. However, steady growth is expected
to continue throughout the forecast period, and the market is expected to grow
at a CAGR of almost 6%.
Request challenges and opportunities
that influence COVID-19 pandemic - Request free sample pages of the
pruritus therapeutic market
The market is driven by the increasing prevalence of pruritus. In
addition, the strong pipeline of expected launches is anticipated to boost the
growth of the pruritus therapeutic market.
Pruritus occurs in various disease conditions such as hematology, renal,
cholesteric, endocrine, and oncology. Nearly 12 million people in the US have
psoriasis and about 7.5 million are diagnosed with one or the other form of
skin diseases that is accompanied by this condition. Also, currently, no
specific medication is available for the treatment of prurigo nodularis. Its
growing prevalence is providing significant growth opportunities for market
vendors to engage in the development of novel pruritus therapeutics. This, in
turn, is driving the growth of the global pruritus market.
Buy 1 Technavio report and get the
second for 50% off. Buy 2 Technavio reports and get the third for free.
View market snapshot before
purchasing
Major Five Pruritus Therapeutic Companies:
Abbott Laboratories
Abbott Laboratories operates its business through segments such as
Established Pharmaceuticals Products, Nutritional Products, Diagnostic
Products, and Medical Devices. The company offers Humira, which is an
injectable drug that is used to treat adults with moderate to severe chronic
plaque psoriasis.
Allergan Plc
Allergan Plc operates its business through segments such as US
Specialized Therapeutics, US General Medicine, and International. The company
offers TAZORAC. It is a retinoid indicated for the topical treatment of plaque
psoriasis.
Astellas Pharma Inc.
Astellas Pharma Inc. operates its business through a unified business
segment. The company offers Protopic. It is a tacrolimus ointment used as a
therapeutic agent for atopic dermatitis.
Cipla Inc.
Cipla Inc. operates its business through segments such as Pharmaceuticals
and New ventures. The company offers ZOFLUT Cream. It contains fluticasone
propionate which has anti-inflammatory, antipruritic, and vasoconstrictive
properties.
GlaxoSmithKline Plc
GlaxoSmithKline Plc operates its business through segments such as
Pharmaceuticals, Consumer healthcare, and Vaccines. The company offers
Fenistil, which is indicated for itchiness caused by dermatoses, urticaria,
insect bites, sunburn, and superficial burns.
No comments:
Post a Comment